Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Long-Term Investments (2016 - 2025)

Historic Long-Term Investments for Tg Therapeutics (TGTX) over the last 5 years, with Q3 2025 value amounting to $48.8 million.

  • Tg Therapeutics' Long-Term Investments rose 423395.56% to $48.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.8 million, marking a year-over-year increase of 423395.56%. This contributed to the annual value of $808000.0 for FY2024, which is N/A changed from last year.
  • As of Q3 2025, Tg Therapeutics' Long-Term Investments stood at $48.8 million, which was up 423395.56% from $28.6 million recorded in Q2 2025.
  • Tg Therapeutics' Long-Term Investments' 5-year high stood at $48.8 million during Q3 2025, with a 5-year trough of $808000.0 in Q4 2024.
  • Its 4-year average for Long-Term Investments is $19.6 million, with a median of $17.3 million in 2021.
  • As far as peak fluctuations go, Tg Therapeutics' Long-Term Investments tumbled by 6509.16% in 2022, and later skyrocketed by 423395.56% in 2025.
  • Over the past 4 years, Tg Therapeutics' Long-Term Investments (Quarter) stood at $35.5 million in 2021, then crashed by 65.09% to $12.4 million in 2022, then tumbled by 93.49% to $808000.0 in 2024, then soared by 5934.28% to $48.8 million in 2025.
  • Its Long-Term Investments stands at $48.8 million for Q3 2025, versus $28.6 million for Q2 2025 and $1.9 million for Q1 2025.